The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs

키워드

참고문헌 (96)

1. Kopfmann S, "Toxin-antitoxin systems on the large defense plasmid pSYSA of Synechocystis sp. PCC 6803", J. Biol. Chem, 288, pp.7399~7409 (2013)
2. Jinek M, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", Science, 337, pp.816~821 (2012)
3. Levasseur A, "MIMIVIRE is a defence system in mimivirus that confers resistance to virophage", Nature, 531, pp.249~252 (2016)
4. Lander ES, "The heroes of CRISPR", Cell, 164, pp.18~28 (2016)
5. Jansen R, "Identification of genes that are associated with DNA repeats in prokaryotes", Mol. Microbiol, 43, pp.10~ (2002)
6. Sontheimer EJ, "RNA. CRISPR goes retro", Science, 351, pp.920~921 (2016)
7. Makarova KS, "Annotation and classification of CRISPR-Cas systems", Methods Mol. Biol, 1311, pp.47~75 (2015)
8. Mei Y, "Recent progress in CRISPR", Cas9 technology, 2016, pp.43, 63~75
9. Horvath P, "CRISPR", Cas, the immune system of bacteria and archaea, 2010, pp.327, 167~170
10. Doudna JA, "Genome editing. The new frontier of genome engineering with CRISPR-Cas9", Science, 346, pp.1258096~ (2014)
11. Mohanraju P, "Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems", Science, 353, pp.aad5147~ (2016)
12. Deltcheva E, "CRISPR RNA maturation by transencod ed small RNA a nd host factor RNase III", Nature, 471, pp.602~607 (2011)
13. Sternberg SH, "DNA interrogation by the CRISPR RNA-guided endonuclease Cas9", Nature, 507, pp.62~67 (2014)
14. Zhang Y, "Comparison of non-canonical PAMs for CRISPR", Cas9-mediated DNA cleavage in human cells, 2014, pp.4, 5405~
15. Jiang F, "Structural biology. A Cas9-guide RNA complex preorganized for target DNA recognition", Science, 348, pp.1477~1481 (2015)
16. Sternberg SH, "Conformational control of DNA target cleavage by CRISPRCas9", Nature, 527, pp.110~113 (2015)
17. O’Connell MR, "Programmable RNA recognition and cleavage by CRISPR", Cas9, 2014, pp.516, 263~266
18. Silas S, "Direct CRISPR spacer acquisition from RNA by a natural reverse transcriptase-Cas1 fusion protein", Science, 351, pp.aad4234~ (2016)
19. Abudayyeh OO, "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", Science, 353, pp.aaf5573~ (2016)
20. Shen B, "Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects", Nat. Methods, 11, pp.399~402 (2014)
21. Ma H, "Multiplexed labeling of genomicloci with d Cas9 and engineered sgRNAs using CRISPRainbow", Nat. Biotechnol, 34, pp.528~530 (2016)
22. Mandegar MA, "CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs", 18, pp.1~13 (2016)
23. Kiani S, "Cas9 gRNA engineering for genome editing, activation and repression", Nat. Methods, 12, pp.1051~1054 (2015)
24. Makarova KS, "An updated evolutionary classification of CRISPR-Cas systems", Nat. Rev. Microbiol, 13, pp.722~736 (2015)
25. Chylinski K, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems", RNA Biol, 10, pp.726~737 (2013)
26. Zetsche B, "Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system", Cell, 163, pp.759~771 (2015)
27. Fonfara I, "The CRISPR-associated DNA-cleaving enzyme Cpf1also processes precursor CRISPR RNA", Nature, 532, pp.517~521 (2016)
28. Tsai SQ, "Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases", Nat. Rev. Genet, 17, pp.300~312 (2016)
29. Cong L, "Multiplex genome engineering using CRISPR", Cas systems, 2013, pp.339, 5~
30. Wang T, "Genetic screens in human cells using the CRISPR-Cas9 system", Science, 343, pp.80~84 (2014)
31. Kuscu C, "Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease", Nat. Biotechnol, 32, pp.677~683 (2014)
32. Jiang W, "RNA-guided editing of bacterial genomes using CRISPRCas systems", Nat. Biotechnol, 31, pp.233~242 (2013)
33. Doench JG, "Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation", Nat. Biotechnol, 32, pp.1262~1267 (2014)
34. Jamal M, "Keeping CRISPR", Cas on-target, 2015, pp.20, 1~20
35. Taylor DW, "Structural biology. Structures of the CRISPR-Cmr complex reveal mode of RNA target positioning", Science, 348, pp.581~585 (2015)
36. Kleinstiver BP, "Engineered CRISPR-Cas9 nucleases with altered PAM specificities", Nature, 523, pp.481~485 (2015)
37. Fu Y, "Improving CRISPR-Cas nuclease specificity using truncated guide RNAs", Nat. Biotechnol, 32, pp.279~284 (2014)
38. Hendel A, "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells", Nat. Biotechnol, 33, pp.985~989 (2015)
39. Liang X, "Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection", J. Biotechnol, 208, pp.44~53 (2015)
40. Morrical SW., "DNA-pairing and annealing processes in homologous recombination and homology-directed repair", Cold Spring Harb. Perspect. Biol, 7, pp.a016444~ (2015)
41. Maruyama T, "Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining", Nat. Biotechnol, 33, pp.538~542 (2015)
42. Song J, "RS-1enhances CRISPR", Cas9- and TALEN-mediated knock-in efficiency, 2016, pp.7, 10548~
43. Chu VT, "Increasing the efficiency of homologydirected repair for CRISPR-Cas9-induced precise gene editing in mammalian cells", Nat. Biotechnol, 33, pp.543~548 (2015)
44. Lin S, "Enhanced homology-directed human genome engineering by controlled timing of CRISPR", Cas9 delivery, 2014, pp.3, e04766~
45. Howden SE, "A Cas9 variant for efficient generation of indel-free knockin or gene-corrected human pluripotent stem cells", Stem. Cell Reports, 7, pp.508~517 (2016)
46. Carroll D., "Genome engineering with targetable nucleases", Annu. Rev. Biochem, 83, pp.409~439 (2014)
47. Kim D, "Digenome-seq: genome-wide profiling of CRISPR-Cas9 offtarget effects in human cells", Nat. Methods, 12, pp.237~243 (2015)
48. Ran FA, "Genome engineering using the CRISPR-Cas9 system", Nat. Protoc, 8, pp.28~ (2013)
49. Frock RL, "Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases", Nat. Biotechnol, 33, pp.179~186 (2015)
50. Ran FA, "Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity", Cell, 154, pp.1380~1389 (2013)
51. Wyvekens N, "Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing", Hum. Gene Ther, 26, pp.425~431 (2015)
52. Guilinger JP, "Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification", Nat. Biotechnol, 32, pp.577~582 (2014)
53. Hara S, "Generation of mutant mice via the CRISPR", Cas9system using FokI-dCas9, 2015, pp.5, 11221~
54. Bolukbasi MF, "DNA-binding-domain fusions enhance the targeting range and precision of Cas9", Nat. Methods, 12, pp.1150~1156 (2015)
55. Wright AV, "Rational design of a split-Cas9 enzyme complex", Proc. Natl. Acad. Sci. USA, 112, pp.2984~2989 (2015)
56. Polstein LR, "A light-inducible CRISPRCas9system for control of endogenous gene activation", Nat. Chem. Biol, 11, pp.198~200 (2015)
57. Zetsche B, "A split-Cas9 architecture for inducible genome editing and transcription modulation", Nat. Biotechnol, 33, pp.139~142 (2015)
58. Slaymaker IM, "Rationally engineered Cas9 nucleases with improved specificity", Science, 351, pp.84~88 (2016)
59. Kleinstiver BP, "High-fidelity CRISPR–Cas9nucleases with no detectable genome-wide off-target effects", Nature, 529, pp.490~495 (2016)
60. Anders C, "Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease", Nature, 513, pp.569~573 (2014)
61. Jinek M, "Structures of Cas9 endonucleases reveal RNAmediated conformational activation", Science, 343, pp.1247997~ (2014)
62. Tsai SQ, "GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases", Nat. Biotechnol, 33, pp.187~197 (2015)
63. Mohammadparast S, "Exceptional expansion and conservation of a CT-repeat complex in the core promoter of PAXBP1 in primates", Am. J. Primatol, 76, pp.747~756 (2014)
64. Choi KY, "A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo", Nat. Protoc, 9, pp.1900~1915 (2014)
65. Pattanayak V, "High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity", Nat. Biotechnol, 31, pp.839~843 (2013)
66. Li L, "Challenges in CRISPR", Cas9 delivery: potential roles of nonviral vectors, 2015, pp.26, 452~462
67. Ran FA, "In vivo genome editing using Staphylococcus aureus Cas9", Nature, 520, pp.186~191 (2015)
68. Kotterman MA, "Engineering adenoassociated viruses for clinical gene therapy", Nat. Rev. Genet, 15, pp.445~451 (2014)
69. Sun W, "Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing", Angew. Chem. Int. Ed. Engl, 54, pp.12029~12033 (2015)
70. Sharei A, "A vector-free microfluidic platform for intracellular delivery", Proc. Natl. Acad. Sci. USA, 110, pp.2082~2087 (2013)
71. Han X, "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation", Sci. Adv, 1, pp.e1500454~ (2015)
72. Wang L, "In vivo delivery systems for therapeutic genome editing", Int. J. Mol. Sci, 17, pp.E626~ (2016)
73. Komor AC, "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", Nature, 533, pp.420~424 (2016)
74. Mao XY, "Brain tumor modeling using the CRISPR", Cas9 system: state of the art and view to the future, 2016, pp.7, 33461~33471
75. Matano M, "Modeling colorectal cancer using CRISPRCas9-mediated engineering of human intestinal organoids", Nat. Med, 21, pp.256~262 (2015)
76. Bosze Z, "The potential impact of new generation transgenic methods on creating rabbit models of cardiac diseases", Prog. Biophys. Mol. Biol, 121, pp.123~130 (2016)
77. Nakamura K, "Generation of muscular dystrophy model rats with a CRISPR", Cas system, 2014, pp.4, 5635~
78. Dow LE., "Modeling disease in vivo with CRISPR", Cas9, 2015, pp.21, 609~621
79. Kato T, "In vivo and in vitro disease modeling with CRISPR", Cas9, 2016, elw031~
80. Kraft K, "Deletions, inversions, duplications: engineering of structural variants using CRISPR", Cas in mice, 2015, S2211~S1247
81. Dow LE, "Inducible in vivo genome editing with CRISPR-Cas9", Nat. Biotechnol, 33, pp.390~394 (2015)
82. Thakore PI, "Editing the epigenome: technologies for programmable transcription and epigenetic modulation", Nat. Methods, 13, pp.127~137 (2016)
83. Black JB, "Targeted epigenetic remodeling of endogenous loci by CRISPR", Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells, 2016, pp.19, 1~9
84. Banan M, "The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian beta-thalassemia patients", Hemoglobin, 36, pp.371~380 (2012)
85. Banan M, "Utility of the multivariate approach in predicting beta-thalassemia intermedia or betathalassemia major types In Iranian patients", Hemoglobin, 37, pp.413~422 (2013)
86. Bauer DE, "An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level", Science, 342, pp.253~257 (2013)
87. Tabebordbar M, "In vivo gene editing in dystrophic mouse muscle and muscle stem cells", Science, 531, pp.407~411 (2015)
88. Courtney DG, "CRISPR", Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12mutation-specific targeting, 2016, pp.23, 108~112
89. Kennedy EM, "Bacterial CRISPR", Cas DNA endonucleases: a revolutionary technology that could dramatically impact viral research and treatment, 2015, pp.479-480, 213~220
90. Rahimpour A, "Development of genetically modified Chinese hamster ovary host cells for the enhancement of recombinant tissue plasminogen activator expression", Malays. J. Med. Sci, 23, pp.6~13 (2016)
91. Lee JS, "CRISPR", Cas9-mediated genome engineering of CHO cell factories: application and perspectives, 2015, pp.10, 979~994
92. "First CRISPR clinical trial gets green light from US panel" (2016)[URL]
93. Richardson CD, "Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA", Nat. Biotechnol, 34, pp.339~344 (2016)
94. Baltimore D, "Biotechnology. A prudent path forward for genomic engineering and germline gene modification", Science, 348, pp.36~38 (2015)
95. Savic N, "Advances in therapeutic CRISPR", Cas9 genome editing, 2016, pp.168, 15~21
96. Gao Y, "Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPRmediated genome editing", J. Integr. Plant Biol, 56, pp.343~349 (2014)

관련 논문AI추천